Alcidion enters FY27 with record revenue and a broader capital toolkit

Record FY26 performance gives Alcidion more capital choices

Alcidion Group Limited (ASX:ALC) has used its annual meeting to present a business that is no longer simply chasing scale. The healthcare technology company reported its strongest financial performance to date for FY26, with revenue up 27% to $51.6 million, underlying EBITDA rising 34% to $6.8 million and operating cash flow increasing 19% to $6.2 million.

The balance sheet adds weight to the result: Alcidion finished 30 June with $20.6 million in cash and no debt. Chair Rebecca Wilson said the company had moved “decisively from transformation to traction”, pointing to a larger base of recurring, multi-year health-system partnerships across Australia, New Zealand and the United Kingdom.

FY27 begins with $50 million of contracted revenue

Alcidion reaffirmed its guidance that FY27 revenue and underlying EBITDA will exceed FY26. As at 30 September, contracted and renewal revenue expected to be recognised during the year stood at $50.0 million, up 38% on the prior corresponding period. That figure provides visibility, but it is not the same as a guarantee that the full-year target will be achieved.

The update builds on the FY27 contracted revenue growth reported in late October, when Alcidion also outlined the launch of its Miya Patient Administration product. The company said further growth should come from expanding existing hospital relationships, adding Miya modules and winning new customers in its established markets and selected international geographies.

Kyra acquisition expands patient-flow footprint

Alcidion highlighted the 29 June acquisition of Kyra Health’s flow products as a key operational step. The deal added 33 customers, 31 of them new to Alcidion, and contributed $3.6 million of annual recurring revenue to the group’s reported $38.3 million ARR at 30 June. Management described the acquisition as immediately earnings accretive and said it strengthened Alcidion’s position in Australia’s patient-flow market, particularly in Queensland.

The company also pointed to multiple flagship customer expansions, a third Electronic Patient Record contract and new or expanded deployments spanning patient flow, virtual care and clinical communications. Its customer base now covers more than 100 healthcare organisations across the UK, Australia and New Zealand, according to the AGM presentation.

Miya platform moves towards patient administration and AI

The strategic pitch is increasingly centred on making Miya a broader system of record rather than a collection of individual workflow tools. Alcidion presented Miya Patient Administration as a newly built modular EPR capability covering registration, admitted care, ambulatory services, reporting, interoperability and security, with the company saying it used artificial intelligence to analyse requirements from its existing patient-administration blueprint.

AI remains a development theme rather than a disclosed revenue line. The company outlined planned capabilities across knowledge retrieval, documentation and summarisation, prediction, analytics and agentic workflows, while acknowledging the need to protect client data and security. No financial contribution or delivery timetable for those initiatives was provided in the AGM material.

Shareholders approve consolidation as buy-back remains selective

Shareholders approved the proposed consolidation of every 10 shares into one, along with the equivalent treatment for performance rights. The resolution passed with 91.34% of votes cast in favour, while the remuneration report received 95.49% support and Rebecca Wilson’s re-election received 97.41%.

The consolidation sits alongside an on-market buy-back of up to 10% of issued capital, or approximately 135 million ordinary shares. Alcidion said the buy-back would be used selectively, with capital also required for Miya investment, market expansion and potential acquisitions. The company has not framed the maximum buy-back capacity as a commitment to purchase the full amount.

Execution now matters more than the headline numbers

For Alcidion, the next test is converting contracted revenue and a broader product suite into sustained growth without diluting the discipline that produced positive cash generation. The AGM presentation identifies expansion into Canada, the Middle East and Southeast Asia, alongside deeper penetration of existing customers, but does not attach financial targets to those opportunities.

The company also commissioned an independent review of its remuneration framework after acknowledging shareholder frustration with the share price. The eventual disclosure will offer a useful signal of how Alcidion intends to align incentives with a more mature, profitable business while it simultaneously pursues growth, capital returns and acquisitions.